Cephalon, A Target Itself, To Acquire Remainder Of ChemGenex
Just a week after purchasing oncology company Gemin X, Cephalon is buying the remaining shares of Australian biotech ChemGenex that it does not already own for $163 million.
Just a week after purchasing oncology company Gemin X, Cephalon is buying the remaining shares of Australian biotech ChemGenex that it does not already own for $163 million.